Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

The proliferative capacity of residual breast cancer (BC) disease indicates the existence of partial treatment resistance and higher probability of tumor recurrence. We explored the therapeutic potential of adding neoadjuvant metformin as an innovative strategy to decrease the proliferative potentia...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Med
Main Authors: Lopez-Bonet, Eugeni, Buxó, Maria, Cuyàs, Elisabet, Pernas, Sonia, Dorca, Joan, Álvarez, Isabel, Martínez, Susana, Pérez-Garcia, Jose Manuel, Batista-López, Norberto, Rodríguez-Sánchez, César A., Amillano, Kepa, Domínguez, Severina, Luque, Maria, Morilla, Idoia, Stradella, Agostina, Viñas, Gemma, Cortés, Javier, Oliveras, Gloria, Meléndez, Cristina, Castillo, Laura, Verdura, Sara, Brunet, Joan, Joven, Jorge, Garcia, Margarita, Saidani, Samiha, Martin-Castillo, Begoña, Menendez, Javier A.
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6947627/
https://ncbi.nlm.nih.gov/pubmed/31835708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8122180
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados